1. Home
  2. SBGI vs SNDX Comparison

SBGI vs SNDX Comparison

Compare SBGI & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SBGI
  • SNDX
  • Stock Information
  • Founded
  • SBGI 1986
  • SNDX 2005
  • Country
  • SBGI United States
  • SNDX United States
  • Employees
  • SBGI N/A
  • SNDX N/A
  • Industry
  • SBGI Broadcasting
  • SNDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SBGI Industrials
  • SNDX Health Care
  • Exchange
  • SBGI Nasdaq
  • SNDX Nasdaq
  • Market Cap
  • SBGI 956.9M
  • SNDX 1.1B
  • IPO Year
  • SBGI 1995
  • SNDX 2016
  • Fundamental
  • Price
  • SBGI $14.36
  • SNDX $16.24
  • Analyst Decision
  • SBGI Buy
  • SNDX Strong Buy
  • Analyst Count
  • SBGI 6
  • SNDX 10
  • Target Price
  • SBGI $20.08
  • SNDX $37.50
  • AVG Volume (30 Days)
  • SBGI 671.2K
  • SNDX 2.9M
  • Earning Date
  • SBGI 08-06-2025
  • SNDX 08-04-2025
  • Dividend Yield
  • SBGI 6.97%
  • SNDX N/A
  • EPS Growth
  • SBGI N/A
  • SNDX N/A
  • EPS
  • SBGI 0.74
  • SNDX N/A
  • Revenue
  • SBGI $3,481,000,000.00
  • SNDX $77,933,000.00
  • Revenue This Year
  • SBGI N/A
  • SNDX $434.67
  • Revenue Next Year
  • SBGI $9.59
  • SNDX $108.62
  • P/E Ratio
  • SBGI $19.36
  • SNDX N/A
  • Revenue Growth
  • SBGI 8.11
  • SNDX 2126.66
  • 52 Week Low
  • SBGI $11.89
  • SNDX $8.58
  • 52 Week High
  • SBGI $18.46
  • SNDX $22.50
  • Technical
  • Relative Strength Index (RSI)
  • SBGI 52.40
  • SNDX 79.83
  • Support Level
  • SBGI $13.39
  • SNDX $15.36
  • Resistance Level
  • SBGI $15.43
  • SNDX $16.33
  • Average True Range (ATR)
  • SBGI 0.68
  • SNDX 0.78
  • MACD
  • SBGI 0.04
  • SNDX 0.31
  • Stochastic Oscillator
  • SBGI 69.77
  • SNDX 96.87

About SBGI Sinclair Inc.

Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: